Relationships among KRAS mutation status, expression of RAS pathway signaling molecules, and clinicopathological features and prognosis of patients with colorectal cancer

doi:10.3748/wjg.v25.i7.808

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 25, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9531)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-8) series, Tables (1-9) series.

Item

Count

PDF

627

WORD

250

HTML

5702

Figures (1-8)

450

Tables (1-9)

450

Sum=7479

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

908

Download

1144

Sum=2052

Feb 21, 2019 (publication date) through Apr 15, 2025

Times Cited of This Article

Times Cited (29)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. Feb 21, 2019; 25(7): 808-823
Published online Feb 21, 2019. doi: 10.3748/wjg.v25.i7.808

Table 5 Relationship between KRAS genotype and expression of downstream proteins in colorectal cancer tissues

Protein	KRAS mutant type group positive rate	KRAS wild-type group positive rate	χ²	P-value
BRAF	74.2% (46/62)	74.6% (100/134)	0.004	0.948
MEK	54.8% (34/62)	58.2% (78/134)	0.196	0.657
ERK	45.2% (28/62)	54.1% (72/133)	1.364	0.243

Citation: Wan XB, Wang AQ, Cao J, Dong ZC, Li N, Yang S, Sun MM, Li Z, Luo SX. Relationships among KRAS mutation status, expression of RAS pathway signaling molecules, and clinicopathological features and prognosis of patients with colorectal cancer. World J Gastroenterol 2019; 25(7): 808-823
URL: https://www.wjgnet.com/1007-9327/full/v25/i7/808.htm
DOI: https://dx.doi.org/10.3748/wjg.v25.i7.808